Faraz Ali

Faraz Ali

Company: Tenaya Therapeutics

Job title: Chief Executive Officer


Mr. Ali was most recently chief business officer at REGENXBIO, where he had accountability for corporate development, commercial planning, portfolio strategy, alliance management and corporate communications. Prior to that, he was a vice president at bluebird bio, where he had accountability for new product planning, program management, patient advocacy and external affairs. Mr. Ali also had roles of increasing global commercial leadership at Genzyme Corporation, where he helped launch multiple first-in-class enzyme replacement therapies for rare diseases. He started his career at General Electric, including technical roles at GE Healthcare and business assignments at GE Corporate. Mr. Ali received his MBA. from Harvard Business School and his B.S. from Stanford University.


Chair’s Closing Remarks 5:15 pm

Read more

day: Day One PM

What to Look Forward to for Gene Therapy in 2024 8:30 am

Market trends and expectations for gene therapies & rare diseases in 2024   Predictions on potential approvals in 2024 Innovative trends & technologies   Evolution of CMC and manufacturing Read more

day: Day One AM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.